Literature DB >> 4083865

Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients.

J A Bosso, P L Townsend, J J Herbst, J M Matsen.   

Abstract

The pharmacokinetics of netilmicin were determined in 10 patients with cystic fibrosis. Mean (+/- standard error of the mean) values for total body clearance and volume of distribution were 2.62 (+/- 0.18) ml/min per kg of body weight and 0.38 (+/- 0.01) liter/kg, respectively, and were considerably larger than the same parameters reported for patients without cystic fibrosis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4083865      PMCID： PMC180338          DOI： 10.1128/AAC.28.6.829

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

2.  The pharmacokinetics of amikacin in children.

Authors:  B Vogelstein; A Kowarski; P S Lietman
Journal:  J Pediatr       Date:  1977-08       Impact factor: 4.406

3.  The chest roentgenogram in cystic fibrosis: a new scoring system.

Authors:  D Brasfield; G Hicks; S Soong; R E Tiller
Journal:  Pediatrics       Date:  1979-01       Impact factor: 7.124

4.  A new prognostic score and clinical evaluation system for cystic fibrosis.

Authors:  L M Taussig; J Kattwinkel; W T Friedewald; P A Di Sant'Agnese
Journal:  J Pediatr       Date:  1973-03       Impact factor: 4.406

Review 5.  The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis.

Authors:  M I Marks
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

6.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

7.  Pharmacokinetics of netilmicin in children with and without cystic fibrosis.

Authors:  H Michalsen; T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

8.  Kinetics of netilmicin in man.

Authors:  J C Pechere; R Dugal; M M Pechere
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

9.  Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

Authors:  P H Beaudry; M I Marks; D McDougall; K Desmond; R Rangel
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

10.  Kinetics of netilmicin and gentamicin.

Authors:  J A Jahre; K P Fu; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875
View more
  6 in total

Review 1.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 2.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 3.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 4.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 5.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 6.  Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.

Authors:  C A Lindsay; J A Bosso
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.